You don't need any special skill sets to recognize the dire picture for Carnival (NYSE:CCL). Recently, S&P Global Ratings downgraded the cruise ship operator's long-term credit rating by three levels to BB-. This cut comes after Moody's Investors Services rated the company as "junk." Naturally, this leaves CCL stock in quite a predicament.Source: Ruth Peterkin / Shutterstock.com To be fair, the negativity isn't unreasonable. After all, it was the Diamond Princess - which is under the Carnival umbrella - that became the face of the novel coronavirus as it was forcibly quarantined off the coast of Japan. Later, other cruise ships suffered the same fate, bringing a black eye to operators like Royal Caribbean Cruises (NYSE:RCL) and Norwegian Cruise Line (NYSE:NCLH).However, there's a case to be made about deeply embattled investments making a comeback. Certainly, I wouldn't recommend shorting CCL stock. With prices discounted almost ridiculously if you didn't understand the...
UBS Head of Women Segment Strategy Carey Shuffman and UBS Managing Director Julie Fox join Yahoo Finance’s On The Move to break down the UBS 'Own Your Worth' Report for 2020....
Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Matt McCall's pick for the contest is Aimmune Therapeutics (NASDAQ:AIMT).Six months ago, I introduced you to Aimmune Therapeutics (NASDAQ:AIMT) as my pick in the Best Stocks for 2020 contest. It's a leading biopharmaceutical that focuses specifically on the unmet needs of people who suffer from food allergies.The recommendation was in anticipation of the approval of its lead drug candidate. That worked out just as expected. Aimmune's treatment for peanut allergies got the green light from the U.S. Food and Drug Administration in January.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat was -- and still is -- a very big deal. Palforzia is the first-ever treatment for peanut allergies, and its approval sent the stock to a fresh one-year high.And then the novel coronavirus hit…The first patients were given Palforzia after the January approval, but for all...
(Bloomberg) -- Colin Huang’s ascent is one for the history books: In just six months, his fortune swelled by $25 billion -- one of the biggest gains among the world’s richest people.His Pinduoduo Inc., a Groupon-like shopping app he founded in 2015, has become China’s third-largest e-commerce platform, with a market value of more than $100 billion. In the first quarter, as the coronavirus pandemic caused most of the nation’s economy to grind to a halt, PDD’s active users surged 68% and revenue jumped 44%, the company said in May.Now Huang, who has overseen the firm as its American depositary receipts have more than quadrupled in less than two years, has stepped down as chief executive officer.At one point, his net worth climbed as high as $45 billion, placing him just behind China’s wealthiest people -- Tencent Holdings Ltd.’s Pony Ma and Alibaba Group Holding Ltd.’s Jack Ma -- on the...
If you are looking for the best ideas for your portfolio you may want to consider some of Ensemble Capital's top stock picks. Ensemble Capital, an investment management firm, is bullish on Starbucks Corp (NASDAQ:SBUX) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its investment […]...
